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A B S T R A C T
Most hemodialysis (HD) patients experience symptoms of depression, pain and fatigue that impair their health-
related quality of life (HRQOL) signiﬁcantly. These symptoms are associated with increased hospitalization and
mortality, mediated by behavioral factors (e.g. non-adherence to medication and dialysis) and biological factors
(e.g. inﬂammatory cytokines). Prior interventions to alleviate symptoms and improve HRQOL showed limited
eﬀectiveness in HD patients and their eﬀect on bio-behavioral mediators is lacking evidence. It is imperative to
improve patient-centered dialysis care and to address call from Kidney Disease Improving Global Outcomes
(KDIGO) guidelines for integration of symptom assessment and management in routine HD-care. Technology-
Assisted stepped Collaborative Care (TĀCcare) is a multi-center randomized controlled trial (RCT) of 150 diverse
HD patients from Pennsylvania and New Mexico, designed to compare the eﬀectiveness of a 12-week stepped
collaborative care intervention (cognitive behavioral therapy, CBT) with an attention control arm of technology-
delivered health education. Collaborative care provides an integrated multi-disciplinary structured management
plan. Furthermore, a stepped approach to pharmacotherapy and/or CBT allows for individualization of treat-
ment according to patients' clinical status, preferences and treatment response. To simplify the delivery of CBT
and to minimize patient and provider burden, we will use live video-conferencing with patients in dialysis units.
We will examine the eﬀect of these interventions on patient symptoms, HRQOL, treatment adherence and in-
ﬂammatory biomarkers. This RCT tests a readily implementable intervention that can be integrated in routine
HD-care and will generate novel and meaningful insights on strategies to alleviate common symptoms and
improve HRQOL in HD.
1. Introduction
Patients with End-Stage Renal Disease (ESRD) on hemodialysis (HD)
experience a symptom burden comparable to advanced cancer patients
[1–4]. Fatigue, pain and depression are among the most debilitating
symptoms, reported by>60%, 50% and 20% of HD patients,
respectively [5–8]. These symptoms often co-exist as “symptom-clus-
ters,” can exacerbate one another, and are independently associated
with poor health-related quality of life (HRQOL) in HD [2,9–12]. Given
their associations with decrements in multiple HRQOL domains, these
symptoms are associated with medication and HD sessions non-ad-
herence [13–15]. Non-adherence, as well as biological factors (e.g.
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inﬂammatory cytokines), likely contribute to increased hospitalization
and mortality in these patients (Fig. 1) [9,15–18]. Additionally to sur-
vival, improvement of these symptoms is extremely important to HD
patients and their caregivers [19,20]. Only recently, the Kidney Disease
Improving Global Outcomes (KDIGO) Controversies Conference on
Supportive Care (2015) advocated for integration of symptom assess-
ment and management into routine ESRD care [21]. Additionally, re-
cent Center for Medicare and Medicaid Services (CMS) criteria for ESRD
Quality Incentive Program mandate reporting of depression screening
and treatment for all patients [22].
Unfortunately, routine treatment approaches for symptoms in HD
patients had limited success [5,7,8]. Although promising, studies on the
eﬃcacy of pharmacotherapy or psychotherapy [such as cognitive be-
havioral therapy (CBT)] for depression in HD are methodologically
limited (small sample size, observational design, lack of adequate
control group, lack of adequate minority racial/ethnic representation)
[23–28]. Data also suggest beneﬁts of analgesic medications for pain;
and of sleep hygiene, exercise and anemia correction for fatigue [7,29].
No studies have tested the eﬃcacy of CBT for pain or fatigue in ESRD.
However, CBT has proven eﬃcacious in similarly symptomatic cancer
patients and is based on a conceptual model that highlights the im-
portance of precipitating and perpetuating factors (e.g. poor sleep,
physical inactivity, and coping strategies) which exist in ESRD patients
[30,31]. Key reasons for poor acceptance and suboptimal results of
prior interventions were: failure to target “symptom-clusters”, com-
bining pharmacotherapy and behavioral-therapy, incorporating patient
treatment preferences, or integrating interventions into existing dia-
lysis-care team-models [8,32,33].
The TĀCcare trial is based on a Stepped-Collaborative Care
Intervention (SCCI) that addresses these barriers to eﬀective treatment
implementation and presents an ideal symptom management strategy
for HD patients (Fig. 2). SCCI emphasizes a more real-world and ﬂexible
intervention that has multiple “active ingredients” (psychotherapy and
pharmacotherapy) and includes a care manager actively monitoring
treatment response, following an evidence-based protocol to modify
treatment content and intensity, and serving as a liaison between the
health-care teams to facilitate integration of mental and physical-health
treatments [34,35]. In SCCI, patients' adherence, treatment response,
preferences and outcomes are monitored actively and treatments are
modiﬁed as needed to achieve the best possible outcome for each pa-
tient. To simplify the delivery of the behavioral therapy component and
reduce the patient and provider burden, the current trial will in-
corporate video-conferencing in dialysis units. This will be the ﬁrst,
multi-center randomized controlled trial (RCT) targeting symptom-
clusters and using a SCCI with technology-based delivery of behavioral
interventions in HD patients. The results will lead to new approaches
for symptom management in HD patients.
2. Methods
2.1. Study overview
This study is a two-site, parallel group, RCT comparing a technology
assisted SCCI (TĀCcare) to technology-assisted health education control
in improving key patient-centered outcomes in 150 HD patients. After
signing informed consent, completing baseline assessments and meeting
eligibility criteria, enrolled patients will be randomized 1:1 to TĀCcare
or technology-delivered health education and will undergo a 12-week
intervention (Fig. 3). The study participants will be recruited using an
approach to limit drop-out while enhancing generalizability and the
main analysis is intention-to-treat. The main patient-centered outcomes
(Aim 1) are: 1) a clinically meaningful change (eﬀect size 0.6) in de-
pression, pain or fatigue (primary outcome); 2) a change in HRQOL and
ecological momentarily assessed composite symptom score of fatigue,
sleepiness and mood (secondary outcomes) after the 12-week interven-
tion. We will also determine the eﬀect of TĀCcare on adherence to
medications, diet and HD treatments (secondary outcomes) (Aim 2) and
we will explore changes in inﬂammatory biomarker levels (Aim 3) after
the 12-week intervention. Since the eﬀect of pharmacotherapy may be
delayed, we will measure these outcomes at 6months and again at
12months to assess the maintenance of the beneﬁts of our intervention.
2.2. Setting and participants
A total of 150 adult chronic HD patients will be recruited from the
two clinical sites at the University of Pittsburgh and the University of
New Mexico which collectively have 20 free-standing dialysis clinics
that vary in geographic areas, size and population served. These clinics
were selected to ensure a diverse HD population with adequate re-
presentation of females and minority groups including African
Americans, American Indians and Hispanic/Latinos.
2.3. Eligibility criteria
Patient inclusion criteria include: a) 18 years or older; b) under-
going thrice-weekly maintenance HD for over 3months; c) English or
Spanish speaking; d) ability to provide informed signed consent; and e)
no evidence of thought disorder, delusions, or active suicidal intent
observed or reported. Patient exclusion criteria include: a) evidence of
thought disorder, delusions or active suicidal intent – observed or re-
ported; b) active substance abuse; c) too ill or cognitively impaired to
participate based on clinicians' judgement; d) anticipated life ex-
pectancy of< 1 year; e) unable or unwilling to adhere to study pro-
tocol; f) participating in another clinical trial or taking an investiga-
tional drug; g) scheduled for living donor kidney transplant within the
next 6months; h) relocating to another dialysis unit within 6months.
We will not exclude patients who are already being treated for pain or
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Fig. 1. Symptom burden, inﬂammation and outcomes in HD patients.
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depression if they screen positive for clinical levels of depression, pain
or fatigue as studies suggest that these symptoms are often undertreated
in HD patients [36,37].
2.4. Screening
Eligible patients will be screened for:
1) Clinical levels of symptoms: Screening will include 9 questions for
depressive symptoms from the Patient Health Questionnaire-9
(PHQ-9), 0–10 point Likert scale of pain (10=worst pain), and
0–10 point Likert scale of fatigue (10=worst fatigue) experienced
within last 2 weeks [38]. Only symptomatic patients who have
clinical levels of at least one of the 3 symptoms (≥10 on PHQ-9
and/or ≥4 on pain scale and/or ≥5 on fatigue scale) will be in-
cluded in the study. This is important because we are targeting
patients with high symptom burden to evaluate the eﬃcacy of
TĀCcare.
2) Readiness for Behavior Change: We will use a 5–item Stages of
Behavior Change questionnaire to assess patient's readiness for
treatment. A clinically signiﬁcant eﬀect size has been shown for the
association between stage of change and psychotherapy outcomes,
suggesting that patients who are in the pre-contemplation stage with
no intention to change behavior in the foreseeable future are un-
likely to actively participate and derive beneﬁt from the treatment
[39]. Thus, we will enroll only those patients who are at least in
contemplation stage of behavioral change for symptom management
(“would be motivated to seek treatment or talk to their doctor about
it”).
2.5. Randomization
After enrollment and completion of baseline assessments, the Study
Coordinating Center at Pittsburgh will assign patients randomly in a 1:1
ratio to either TĀCcare or health education arm, using a computer
generated randomization schedule. Randomization will be stratiﬁed by
the two clinical sites, age (< 60 and ≥60 years) and the Charlson
comorbidity index (< 4 and ≥4) to minimize the likelihood of group
imbalance in these potentially confounding variables. Permuted block
design with random block sizes will be used, but the block sizes will not
be disclosed to ensure allocation concealment.
2.6. Cross-contamination
Patients in both arms will receive an intervention delivered using
video-conferencing. Thus, even though patients at outpatient dialysis
clinics are in close proximity to fellow patients, we expect that any
chances of cross-contamination between study arms is minimal.
Moreover, even if the patients are in diﬀerent arms at the same unit and
interact with each other, these interactions are likely to be brief and
unlikely to have any sustained eﬀect on our outcomes of interest.
Furthermore, the care coordinator for the intervention and control arm
will not be the same person to ensure there is no unintentional con-
tamination from the study staﬀ while delivering the intervention.
Lastly, although there is a possibility that the renal providers could start
recognizing and recommending symptom management in the control
arm patients, this is unlikely given reluctance of patients and providers
regarding pharmacotherapy alone, and patient burden associated with
in-oﬃce CBT.
2.7. Blinding
Neither the patients nor the PI can be blinded due to the nature of
the study intervention. However, research staﬀ assessing patient-cen-
tered outcomes will be blinded to the group assignment.
3. Treatment intervention study arms
A) Technology Assisted Stepped Collaborative Care Intervention
(TĀCcare)
Patients randomized to the intervention arm will receive a stepped-
care approach of pharmacotherapy and/or CBT for a 12-week period.
The intervention will target one or more symptoms based on patients'
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Fig. 2. TACcare model of care.
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report of clinical levels of each symptom and patient preference. A local
care coordinator at each clinical site will be assigned to each patient.
During weekly online video-conferencing sessions, care coordinators
will engage the patient actively, encourage and monitor treatment ad-
herence, and assess response and side-eﬀects. Both clinical sites have
secure and established telemedicine portals that are routinely used for
clinical care and research (Vidyo at University of Pittsburgh and Echo
Zoom at University of New Mexico). These live video-based face-to-face
sessions will be conducted during one of the thrice weekly HD sessions
at the dialysis unit with optional privacy screen. For each dialysis unit,
the study will provide iPads, portable secure Wi-ﬁ hotspot, wireless
headphones and microphones. Similar to our pilot study (manuscript in
preparation), these devices will be pre-programmed to ensure patient's
ease and independence of use with minimal training, even among the
elderly or those with limited technology experience, thus causing
minimal additional burden for the dialysis staﬀ. If there are any medical
emergencies during the HD session, the video-based session will be
cancelled and rescheduled once the patient is clinically stable. If the
patients have the needed technology at home, they will have the option
of doing these video-conferencing sessions at home.
B) Stepped Approach to Individualize Treatment
Treatment options include pharmacotherapy or CBT or both, based
on patient's symptom severity and preference. As the causes for fatigue
in these patients are multifactorial [7,40], fatigue management algo-
rithm will include assessment of depressive symptoms, sleep quality,
pain, physical inactivity and medication side-eﬀects and these con-
tributing factors will be addressed as needed. In addition, we will en-
sure that dialysis dose and hemoglobin are in target ranges.
At the ﬁrst weekly video-conferencing session, the care coordinator
will identify which symptom/symptoms the patient would like to ad-
dress, explain the risk and beneﬁts of treatment options in a way that is
tailored to the patient's health literacy level, stress the voluntary nature
of their treatment preferences, and choose a treatment plan based on
shared decision-making. Subsequently, the care coordinators will con-
duct weekly 45 to 60-min video-conferencing sessions over 12 weeks
and will tailor behavioral therapy sessions and/or recommend phar-
macotherapy based on an evidence-based protocol. Principles for
measurement-based care will be followed every 2 weeks, i.e. changes to
treatment will be based on assessment of response to treatment, severity
of symptoms and side eﬀects of treatment [41]. Treatment response and
patient preferences will inform care coordinator's decision to modify
the treatment for which they will follow an evidence-based protocol to
add/intensify psychotherapy and/or pharmacotherapy.
C) Psychotherapy/Cognitive Behavioral Therapy
A short-term focused psychotherapy approach called CBT will be
employed to reduce the symptoms of depression, pain and fatigue and
will be individualized based on patient's symptom severity, preferences
and treatment response. This American Psychiatric Association re-
commended approach helps patients learn self-help skills to deal with
real-life issues [42]. CBT has been shown to be highly eﬃcacious with a
moderate eﬀect size in the management of these symptoms [43]. CBT
strategies were adapted for HD patients to address challenges and needs
in the context of ESRD and HD-dependence and were tested in our pilot
study (manuscript under preparation). Speciﬁc CBT modiﬁcations in-
cluded: [1] behavioral/psycho-education emphasizing the potential
contribution of the diagnosis and treatment of ESRD that contributes to
the symptoms burden; [2] identiﬁcation of negative thought patterns
regarding these symptoms and cognitive restructuring; [3] developing
pleasant activities and strategies while considering the limitations of
individuals with ESRD on HD; [4] identifying and resolving commu-
nication diﬃculties that may exist between the patient and his/her
family or medical team that prevents management of symptoms; [5]
relaxation and/or guided imagery; and [6] facilitating the under-
standing of how core beliefs and assumptions, that may be associated
with ESRD and/or dialysis, may prevent eﬀective symptom manage-
ment.
D) Pharmacotherapy
The research team will follow an evidence-based protocol to re-
commend whether a medication should be initiated, changed or in-
tensiﬁed. For pain management we will use the World Health
Organization 3-step analgesic ladder modiﬁed to adjust medication
dosage for HD. Such an approach has also been developed by the Mid-
Atlantic Renal and Kidney End-of-Life Coalitions through support by
the Center of Medicare and Medicaid Services [44]. This approach has
been successfully used in HD patients and has been highly eﬃcacious in
controlling pain in over 95% of participants [29]. Pain medication al-
gorithms will be based on whether the patient has neuropathic pain,
nociceptive pain or both. Pharmacological treatment of depression will
be based on eﬃcacy and safety evidence in HD patients and dose ad-
justment for HD will be recommended as appropriate [33,45,46]. The
research team including nephrologists and internist with symptom
management expertise, along with clinical psychologist will make
medication recommendations. These providers have training and ex-
perience with pharmacotherapy for symptom management. The
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Fig. 3. Overview of TACcare study design.
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recommendations will be conveyed to the patients' primary care pro-
vider (PCP) and/or nephrologist by the care coordinator, who will also
monitor anti-depressant and analgesic medication adherence and side
eﬀects during weekly sessions. Once the patient's PCP and/or ne-
phrologist approve of the medication change, the care coordinator will
facilitate implementation of the treatment by communicating and co-
ordinating with the dialysis team and pharmacy if needed, so as to
minimize burden on dialysis staﬀ. The research team will not prescribe
or provide any medications. To ensure that patient's PCP and/or ne-
phrologist prescribe the recommended by the study medications, we
will conduct regular educational and outreach meetings, and will
communicate regularly with the physicians throughout the study
period.
E) Collaborative Care
An important aspect of TĀCcare is the integration of care provided
as part of research with the patient's routine clinical care. The care
coordinators will serve as a liaison between the patient and other health
care professionals within the patients' medical team. This is important
for providing a multi-disciplinary approach to the patient's physical and
mental health, for aligning symptom management with the patient's
overall plan of care, and for ensuring patient acceptance and adherence
to the study team's recommendations. To facilitate such collaboration,
the care coordinator will communicate (via email or phone or personal
meeting) with the dialysis team at least monthly and whenever medi-
cation changes are recommended; participate in monthly dialysis care
plan meetings whenever possible, and will discuss any pertinent issues
with the dialysis care team (nephrologist, nurses or social worker) at
least monthly. We will record the type and frequency of communication
with the care team.
The care coordinator will also participate in clinical dialysis care
plan meetings and will provide recommendations as appropriate. The
care coordinators are Master's level behavioral therapists who received
speciﬁc training in cultural competence on HD-speciﬁc issues and will
work closely under the supervision of a local study psychologist.
3.1. Technology assisted health education attention control
Patients randomized to this study group will be provided with iPads
during HD (same as the intervention group) and will have weekly
sessions to match the frequency of contact in the intervention group. To
match the attention and expectations of patients in this group, a care
coordinator will use video-conferencing to deliver health education.
Although weekly sessions with care coordinator would have been ideal,
this is not ﬁnancially feasible. Thus, these sessions will alternate with
sessions in which access to educational videos and online educational
material from the National Kidney Foundation (NKF; www.nkf.org) will
be provided. Topics relevant to ESRD such as transplantation, heart
health, immunizations and age appropriate cancer screening, etc. will
be covered.
3.2. Rationale for attention control in study design
It is essential to compare TĀCcare to a control group that receives a
treatment that approximates the amount of time and attention received
by the treatment group but is unlikely to have a speciﬁc eﬀect on the
study outcomes. This approach examines the rival hypothesis that im-
provements in the dependent variable occur because of participant
expectancy and the attention received during the course of the treat-
ment rather than from the treatment itself (the so-called Hawthorne
eﬀect) [47]. The attention control intervention must be feasible and
relevant to the needs and health of the participants and should also be
designed to engage participants and to avoid dropouts or selection
biases based on the requirements of the experimental intervention [48].
These concerns have factored into our selection of a health education
attention control for this study since it is a key issue in patients un-
dergoing maintenance HD, yet it is unlikely to inﬂuence our primary
outcomes. Comparison to an attention control group will reduce the
variability of factors and biases that might inﬂuence the outcomes,
enhance the interpretability of the study results and enable evaluation
of the true eﬀects of our intervention.
3.3. Intervention ﬁdelity and monitoring
To maintain internal validity and enhance intervention ﬁdelity (e.g.,
consistency across care coordinators and adherence to treatment pro-
tocol), care coordinators will follow a study manual speciﬁc for the
study arm and will receive standardized training in dialysis-speciﬁc
CBT or health education. Fidelity will be assessed by reviewing 10% of
randomly selected audiotaped video-conferencing sessions, and ﬁdelity
checklist, and feedback will be provided to the study staﬀ.
3.4. Duration of intervention and follow-up
Each participant will be treated in the assigned group for 12 weeks,
death, or loss to follow-up (withdrawal from study, transfer of dialysis
clinic, change to peritoneal dialysis or transplantation). The length of
intervention was selected based upon national guidelines re-
commending 8–12weeks of weekly CBT or initial pharmacological
treatment of depression [49,50] as well as our prior results showing
successful eﬃcacy of a similar 12-week intervention in cancer patients
[51]. If there is any acute change in patient's medical condition/hos-
pitalization during the intervention period, patients will be re-eval-
uated for their ability and interest to continue participation once
medically stable. If needed, the intervention period will be prolonged to
complete a total of 12 sessions so that patients have an opportunity to
receive adequate treatment and derive cumulative beneﬁt. Outcomes
will be assessed again at 6months to evaluate the intermediate eﬀect of
intervention, as it is possible that some patients may not receive in-
tensiﬁed interventions (including pharmacotherapy) until late in the
window for intervention and will likely not have an immediate eﬀect on
the outcomes. A number of studies and meta-analyses evaluating long
term eﬀect of 8–12weeks of CBT or collaborative care on depression,
fatigue, or pain show sustained beneﬁt at 12months [52–56]. Whether
such sustained eﬀects are seen in this patient population, remains to be
evaluated. Thus, we are evaluating the eﬀects of TACcare at 6months
and 12months to assess the long-term eﬀect of our intervention.
4. Data collection and measures
4.1. Patient-reported outcomes
Instruments with sound psychometric properties in HD patients
have been selected to assess a variety of health domains including the
outcomes of interest and potential mediators of outcomes such as sleep
quality, anxiety and social support (Table 1). These instruments will be
administered centrally by blinded interviewers using computer-assisted
telephone interviewing (CATI) which provides high rates of data col-
lection, limits selection bias and minimizes study burden [57]. Self-
administered questionnaires may be more diﬃcult to complete for the
elderly, minority groups, those with high comorbidity and may exclude
patients with low literacy, visual problems and diminished dexterity,
creating selection bias [58]. The University Center for Social & Urban
Research (UCSUR) at the University of Pittsburgh will administer CATI
through trained interviewers. This approach was used in the Frequent
Hemodialysis Network (FHN) Trial and showed high rate of data cap-
ture in HD patients [57]. The anticipated time for the assessment is
20–30min. To minimize potential confounding from the eﬀects of the
HD procedure, the assessments will be performed on a non-dialysis day
at the participant's home. Assessments will be done at baseline, after
12 weeks of intervention (primary outcome) and at 6 and 12-month
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follow-up.
4.2. Measuring symptom severity and variability in real-time using
ecological momentary assessment (EMA)
EMA is a tool to evaluate patient symptoms prospectively and re-
peatedly in real-time, in the patient's natural environment, and while
minimizing respondent burden [59]. Whereas conventional, recall-
based questionnaires may fail to capture daily and diurnal variation in
symptoms seen in HD patients, resulting in misclassiﬁcation bias, EMA
is well suited to ensure high-ﬁdelity ascertainment of symptoms [60].
Because EMA is well suited to identify those who develop symptoms in
a particular context, it could prove useful for recognizing patients who
develop post-dialysis fatigue, a debilitating, prevalent, but under-
studied symptom [61,62]. EMA data collection will be operationalized
centrally by UCSUR at the University of Pittsburgh. Subjective fatigue/
sleepiness, mood, and cognitive alertness will be assessed using a 19-
item questionnaire Daytime Insomnia Symptom Scale (DISS) [63], ad-
ministered via an interactive voice response system using the patient's
cellphone (or a study cellphone if the patient does not have one). Re-
sponses on a 7-point Likert scale for each question, with higher scores
representing greater endorsement of a particular symptom, will be
collected and scored to derive a composite symptom severity score of
fatigue, sleepiness and mood. Participants will complete the DISS 4
times daily for 7 consecutive days with each assessment generally re-
quiring 2 to 6min. High patient adherence of over 80% was seen using
a similar protocol in our previous study with 55 HD patients completing
1252 of 1540 possible assessments, which did not diﬀer by dialysis day
[60]. To minimize patient burden, EMA will be conducted only at
baseline and at 12 weeks post intervention.
4.3. Measuring treatment adherence
Treatment adherence will be assessed at baseline, 12-week post
intervention and at 6- and 12-month follow-up. Medication and dietary
adherence will be assessed by using four independent sources: a) self-
reported adherence using the 8-item Morisky Medication Adherence
Scale (MMAS-8) which also includes items on medication taking be-
haviors, thus enabling identiﬁcation of barriers to adherence. This scale
is easy to administer, has excellent validity and reliability in patients
with chronic conditions, even among those with low literacy [64]. Such
self-reported measures have been shown to have moderate to high
concordance with objective measures [65]. This scale will be ad-
ministered centrally by blinded interviewers using computer-assisted
telephone interviewing by UCSUR; b) Medication and/or dietary ad-
herence will also be deﬁned by absolute serum phosphorus level<
6.0mg/dL or> 1mg/dL decline in serum phosphorus from preceding
month if absolute serum phosphorus level is> 6.0 mg/dL, measured as
a part of routine clinical care [66,67]; c) Fluid restriction adherence
will be determined by inter-dialytic weight gain percentage (of post
dialysis weight over preceding one month). Those with inter-dialytic
weight gain over3.5% will be classiﬁed as non-adherent [68]; d)
Medication adherence will also be assessed by verifying pharmacy reﬁll
rates for antidepressant, analgesic and antihypertensive medications.
Dialysis adherence data will be obtained by review of dialysis treatment
records. Non-adherence with dialysis will be deﬁned by the percentage
of all dialysis sessions skipped and/or requested by the patient to be
shortened by ≥10min over the 12-week intervention period. Dialysis
sessions missed due to hospitalization will not be included as a skipped
treatment.
4.4. Measuring selected pro/anti-inﬂammatory cytokines
Selected cytokines (high sensitivity C - reactive protein; hs-CRP,
Interleukin; IL-6, IL-10 and Tumor Necrosis Factor; TNF-α) were chosen
based on their reported associations with the outcomes of interest
[9,16,18,69]. All blood samples will be shipped at regular intervals and
cytokine measurements will be performed centrally at the University of
Pittsburgh. We will collect 10mL of blood drawn pre-dialysis at base-
line, post 12-week intervention and at 6-month follow-up. Serum will
be aliquoted within 4 h of the blood draw, shipped on dry ice and stored
at −80 °C for batch analysis. Cytokine levels will be measuring using
Luminex™ bead-set (Millipore Corporation, Billerica MA and Luminex™
100 IS apparatus, Austin TX) in accordance with the manufacturer's
instructions using standardized validated assays and operating proce-
dures.
4.5. Descriptors and potential covariates
Baseline patient data collection will include socio-demographic data
such as age, gender, race, ethnicity, education, marital and employment
status, household income, etc. The patient's clinical characteristic such
as years on dialysis, comorbid conditions, concomitant medications,
etc. along with data on hospitalizations, mortality and transplantation
Table 1
Patient-Reported Outcome (PRO) instruments (Appendix).
Questionnaire Items Domains Psychometric properties
Beck Depression Inventory-II (BDI-II) 21 Depression Excellent internal consistency, test-retest validity and high sensitivity, speciﬁcity
and responsiveness to treatment in HD population [46,101]
Functional Assessment of Chronic Illness Therapy
Fatigue (FACIT-F)
13 Fatigue Excellent internal consistency, test-retest reliability, responsiveness to
interventions and good correlation with SF-36 measured fatigue in HD patients
[102,103]
Brief Pain Inventory (BPI) Short form 9 Pain Extensively used in HD, Excellent construct validity, reliability and
responsiveness to treatment [104]
Pittsburgh Sleep Quality Index (PSQI) 19 Sleep quality Good internal homogeneity, test-retest reliability, discriminant validity, is
responsiveness to treatments and has been used in the ESRD population [105,106]
Medical Outcomes Study Short Form-12 (SF-12) 12 Health-related quality of life The SF-12 scores have excellent intra-class correlation of 0.94 with the SF-36
[107]. SF-36 is commonly used in HD patients, and has been extensively tested for
reliability and validity in HD patients, well-accepted, responsive to clinical
change [57,108]
Multi-dimensional Scale of Perceived Social Support 12 Perceived social support Has 3 subscales—family, friends, and signiﬁcant others, has good internal and
test-retest reliability and has been used in ESRD patients [109,110]
Generalized Anxiety Disorder-7 (GAD-7) scale 7 Anxiety Excellent internal consistency, reliability and validity in the general population
[111]
NIH Patient Reported Outcomes Measurement
Information System (PROMIS) Adult Global Health
questionnaire.
29 Physical function, fatigue,
pain, emotional distress, sleep
These domains have excellent internal consistency, convergent validity and
signiﬁcant diﬀerences between health and disease [113]
Physical Activity Scale for Elderly (PASE) 10 Physical activity Measures physical activity over last 7 days and has been shown to correlate with
accelerometry data in HD patients [114]
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will be obtained from patient interviews and medical chart abstraction.
Routine monthly laboratory assessment done by the dialysis clinics will
be extracted.
5. Adverse events and serious adverse events
Adverse events (AEs) and serious adverse events (SAEs) will be
collected every 2 weeks and whenever the study team learns of an event
between the biweekly assessments during the intervention period.
These will also be collected at 6- and 12-month follow-up, during which
patients will be asked to report all SAE/AEs since the last assessment.
The pre-speciﬁed serious adverse events include – death, hospitaliza-
tion/ER visit, bleeding requiring transfusion or hospitalization (due to
possible selective serotonin reuptake inhibitor mediated reduction in
platelet aggregation), medication overdose requiring ER visit/hospita-
lization (as determined by review of medical records) and acute suicidal
intent. Relatedness of AE/SAEs with study interventions, especially
with medications prescribed for symptom management, will be re-
viewed by external Adverse Events committee and reported.
6. Side eﬀects and tolerability data
The side eﬀects and tolerability data will be collected every 2 weeks
in both study arms. The side eﬀects will be collected using the modiﬁed
Patient Related Inventory of Side Eﬀects (PRISE) questionnaire [70].
This 20-item questionnaire asks about occurrence and tolerability of 20
common side eﬀects. We will also add an open-ended question to record
any other symptoms that patients might have. Although this ques-
tionnaire was developed and used to assess side eﬀects of anti-
depressant medications, we will use the same questionnaire for asses-
sing side eﬀects and tolerability of pain medications because of
signiﬁcant overlap in the commonly reported side eﬀects of these
medications.
7. Outcomes
The primary outcome of the trial is clinically meaningful change
(eﬀect size 0.6) in depression, pain or fatigue as ascertained blindly by
the Beck Depression Inventory-II (BDI-II), Functional Assessment of Chronic
Illness Therapy Fatigue (FACIT-F) and Brief Pain Inventory (BPI) Short
form questionnaires respectively, after a 12-week intervention as com-
pared to control arm. We used eﬀect size (ES) i.e. standardized mean
diﬀerence instead of raw mean diﬀerence as our outcome as this places
the emphasis on the most important aspect of an intervention - the size
of the eﬀect - rather than its statistical signiﬁcance. Moreover, in our
study the 3 symptoms will be measured using diﬀerent instruments
with varying scales, and ES facilitates standardizing the observed
changes in these symptoms. By quantifying the magnitude of the dif-
ference between the two study groups, ES gives a more complete and
clinically relevant picture of health status change. Cohen's d eﬀect size
of 0.6 is considered moderate size and is likely to translate into clini-
cally meaningful improvements in the symptoms [71]. Secondary pa-
tient-reported outcomes include change in HRQOL and EMA-measured
composite score of fatigue, sleepiness and mood after 12-week inter-
vention. Additional secondary outcomes include adherence to medica-
tions, diet and HD treatments; as well as changes in levels of biomarkers
of inﬂammation.
7.1. Statistical analysis
Distributions of baseline characteristics will be compared between
the groups to assess eﬀectiveness of randomization, and statistical dif-
ferences will be accounted for as covariate in secondary adjusted ana-
lyses. All primary analyses will be adjusted for the variables used in
stratiﬁed randomization (site, age, and comorbidity) and unadjusted
analyses will also be reported per CONSORT recommendations [72,73].
The stratiﬁcation variables are potentially prognostic of the outcomes,
which likely will make the adjusted analyses more eﬃcient than un-
adjusted [74,75]. The primary analyses will use the ‘intent-to-treat’
approach in which subjects are analyzed in their assigned group, re-
gardless of treatment adherence, withdrawal or deviation from pro-
tocol. We will also perform per-protocol analysis of patients with>
75% and>50% average adherence based on medication and/or CBT
adherence to examine the impact of adherence and protocol deviations.
General linear mixed models (GLMMs) will be used for inferential
analyses of primary and secondary outcomes. Unless otherwise speci-
ﬁed, all tests will be conducted using two-sided 5% level of signiﬁcance.
We will report our ﬁndings according to the CONSORT guidelines [76].
7.2. Primary outcomes
The three primary patient-reported outcome measures are changes
in depression, pain or fatigue as ascertained blindly by the BDI-II,
FACIT-F and BPI questionnaires respectively, after a 12-week inter-
vention. Changes in all symptom levels will be assessed and analyzed
for each patient. For example, if a patient enters the study because of
signiﬁcant depressive symptoms, we will also assess changes in their
levels of fatigue and pain, in addition to changes in depressive symp-
toms. The rationale for this is that many of these symptoms co-exist,
and treatment of one symptom may aﬀect other symptom levels. Also, it
may be that patients may not self-perceive some symptoms. For ex-
ample, if during the course of the intervention, it becomes apparent that
patient's fatigue is more likely a manifestation of underlying depressive
symptoms, then they will be oﬀered CBT/medications for depression, in
addition to CBT for fatigue. We will use Benjamini-Hochberg correction
to maintain a false-discovery-rate of 5% when testing each of the three
primary symptom outcomes [77]. Analyses will use GLMM for each
outcome with ﬁxed treatment group (TĀCcare or health education),
time (baseline, 3, 6, and 12months), and group by time interaction,
adjusting for variables used in the stratiﬁed randomization. The inclu-
sion of the random patient intercepts will account for the within-patient
correlation due to repeated measures. The group by time interaction
captures the treatment eﬀect. This model will be used to test our pri-
mary hypothesis of treatment eﬀect after 12 weeks of intervention
(immediate eﬀect). In a secondary analysis, we will also test inter-
mediate (6months) and sustained (12months) improvements in out-
comes. Although we expect patient characteristics to be balanced be-
tween groups due to randomization, we will add baseline factors found
to be diﬀerent between groups in secondary adjusted analyses.
7.3. Secondary outcomes
Our secondary patient-reported outcomes are changes in HRQOL
(SF-12 mental and physical component score) in TĀCcare versus control
arm after a 12-week intervention. EMA-measured composite symptom
severity score will be evaluated at baseline and post-intervention
(12 weeks). Adherence outcomes include adherence to medications,
diet and dialysis treatments (all continuous variables) measured at 12-
weeks, and at 6- and 12-months follow-up. Biomarkers of inﬂammation
include hs-CRP, IL-6, IL-10, and TNF-α measured at baseline, 12-week,
and 6-months follow-up. GLMM will also be used to analyze these
outcomes. Benjamini-Hochberg correction will be applied to the bio-
marker analyses. We will also assess the bi-directional association and
calculate correlations between the biomarkers and symptoms.
Moreover, we will examine how adjusting for the biomarkers inﬂuences
the TĀCcare eﬀect on the symptoms, and how adjusting for the symp-
toms inﬂuences the eﬀect on the biomarkers.
7.4. Subgroups
The response to treatment interventions may diﬀer among certain
patient subgroups. Thus, to explore heterogeneity of intervention
M.-E. Roumelioti et al. Contemporary Clinical Trials 73 (2018) 81–91
87
eﬀects, we will examine pre-speciﬁed subgroups including age – age
≤65, age>65; sex – male, female; race – white, black, others;
Charlson comorbidity index –<4, 4 or more; and dialysis vintage
≤1 year, vintage>1 year.
7.5. Missing data
The extent, reasons, randomness of missing data will be examined to
identify possible covert missing data mechanisms. Baseline character-
istics and intermediate outcomes among those who do or do not com-
plete the study will be compared. The primary analytical approaches
(GLMMs) can manage data that are missing (i.e., either missing com-
pletely at random or missing at random).
7.6. Sample size and power
We powered our study to detect a clinically meaningful diﬀerence in
our primary outcomes – depression, pain, or fatigue – after 12 weeks of
intervention while considering feasibility of subject recruitment. Since
there is no validated composite endpoint consisting of the 3 outcomes,
we will test the eﬀect of TĀCcare on each of the outcomes. In order to
address the issue of multiple testing of our primary outcome, we cal-
culated power controlling for False Discovery Rate (FDR) of 5% using
the Benjamini-Hochberg correction [77]. To be more conservative, [1]
we used a two-sided two-sample t-test in the calculations and [2] as-
sumed that the intervention has a true eﬀect on exactly one endpoint.
Our primary analysis will compare groups after 12 weeks inter-
vention using contrast from a mixed model that includes all time points
(baseline, 12 weeks, 6 months, and 12months). By using all available
longitudinal data, our primary analytical approach would be more ef-
ﬁcient than t-test and would provide greater power to detect diﬀer-
ences. We will also have increased power if the intervention has real
eﬀect on more than one endpoint. The projected total sample size is
150, or 75 per randomization group. After accounting for the estimated
10% lost-to-follow-up, the eﬀective total sample size is 136. Our sample
size provides 88% power to detect an eﬀect size of 0.6 controlling for
5% FDR for 3 endpoints assuming a true diﬀerence exists in 1 out of 3
endpoints. If diﬀerences exist on 2 of 3 endpoints, we will have 89%
power to detect an eﬀect size of 0.5. The detectable eﬀect size is con-
sistent with what we observed in our study of SCCI in cancer patients
(eﬀect size was 0.7 for depression, 0.6 for pain and 0.3 for fatigue,
respectively) [51]. From prior studies, the range of estimated standard
deviation for BDI score (depression) was 7.5–9.8, for FACIT-F (fatigue)
was 10.9–15.0, for BPI (pain) was 1.2–2.6 (for BPI, 1-point change is
considered clinically important) [ 51,78,79]. The eﬀect size of 0.6 is
equivalent to a mean diﬀerence of 4.5–5.9 in BDI score, 6.5–9.0 for
FACIT-F, and 0.7–1.6 for BPI. These eﬀect magnitudes are well within
the range of diﬀerences observed in symptom treatment trials and are
considered to be clinically meaningful [51,78,79].
Our sample size is also suﬃcient to detect eﬀect sizes observed in
the literature for our secondary outcomes (HRQOL; composite score of
fatigue, sleepiness, and mood measured by EMA) [51,60]. For the
biomarker analyses, we have 81% power to detect an eﬀect size of 0.5 if
a diﬀerence exists in 2 of 4 biomarkers to be tested.
8. Protection of human subjects
The study protocol has been approved by the Institutional Review
Board (IRB) at the Universities of Pittsburgh and New Mexico. Although
this trial involves minimal risk, we will implement a data and safety
monitoring plan at multiple levels to ensure the safety of participants
and the validity and integrity of the data. An independent Data Safety
and Monitoring Board will oversee the conduct of the study. Safety and
tolerability will be monitored in the study as outlined before. If a pa-
tient reports suicidal or homicidal ideation or abuse to another in-
dividual, the study psychologist will evaluate and facilitate appropriate
treatment, referral and notiﬁcation of authorities as needed. For
chronic pain management, opioid management strategies have been
adapted from the Center for Medicaid and Medicare's Opioid Misuse
Strategy 2016 guidelines. If recommendation for opioid use is made,
patients will be informed of the risks, beneﬁts and limitations of
therapy. Opioid use will be monitored rigorously using the
Pennsylvania and New Mexico Prescription Drug Monitoring Program
System and the patient's physicians will be informed. Use of opioid
contract will be recommended and the lowest possible dose will be
used. Dose adjustments will be recommended cautiously. Screening and
identiﬁcation of patients who may be at high risk for aberrant behaviors
will occur at the initiation or dose escalation of opioid therapy using the
validated Opioid Risk Tool [80]. In patients identiﬁed as high risk for
opioid misuse, referral to a pain management specialist will be re-
commended. For all patients on opioids, the study team will administer
the Current Opioid Misuse Measure (COMM) every month to monitor
opioid use/misuse. For patients with score ≥9 (positive score) on
COMM, indicating current opioid misuse, referral to a specialized pain
management service such as pain clinic will be considered. Opioid use
and dosage in both arms will be reported at the end of the study.
9. Discussion
There is an urgent need to test newer approaches for symptom
management in HD patients, given the high symptom burden, its ne-
gative health consequences and lack of optimal treatment options. Since
depression, pain and fatigue often co-exist as “symptom clusters” and
may exacerbate each other, an intervention targeting multiple symp-
toms simultaneously is warranted. TĀCcare is the ﬁrst intervention of
any kind to target three of the most debilitating ESRD-related symp-
toms, rather than individual symptoms of fatigue, pain and depression.
This randomized controlled trial will build on a stepped-approach for
pharmacotherapy and/or behavioral-therapy and will allow for in-
dividualization of treatment according to patient's clinical status, pre-
ferences and treatment response. Additionally, using a collaborative
multi-disciplinary approach, the patients' symptom management will be
integrated with overall model of dialysis care, thus increasing patient
acceptability and adherence. TĀCcare addresses the KDIGO call in 2015
for integration of symptom assessment and management in routine
ESRD care [21].
The high symptom burden in this population is associated not only
with poor HRQOL but also with increased mortality. In fact, depression
has been associated with a 45% increased risk of death, based on a
meta-analysis of over 67,000 ESRD patients [81]. Similarly pain fre-
quency and intensity have been signiﬁcantly associated with increased
mortality [32]. In addition, a 10-point increase in fatigue score on the
SF-36 vitality subscale is associated with a 10% increase in mortality
(p < 0.001) in this population [9,10]. Unfortunately, health care
providers are largely unaware, untrained and often under-recognize
patient symptoms. We have demonstrated that the sensitivity of renal
providers' recognition of HD patients' depression and pain was<20%
and was 50% for fatigue [82]. Given the focus on biochemical and
dialysis-related targets in the current model of dialysis care, it is not
surprising that providers and patients have divergent clinical and re-
search priorities [82,83]. As a result, many patient symptoms go un-
treated despite available treatment options. For example, in a study of
ESRD patients starting dialysis, only 16% of the depressed patients were
receiving any depression treatment [37]. Similarly, 75% of the 200 HD
patients with reported pain were found to have ineﬀective pain man-
agement [36].
TĀCcare intervention design takes into account several important
considerations for symptom management in HD. Firstly, it oﬀers a
choice of pharmacotherapy and behavioral therapy in a stepped-care
approach, thus providing a real-world intervention allowing for in-
corporation of patient preferences. A stepped care intervention may be
deﬁned as “the least costly, least intensive, and least restrictive
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treatment judged suﬃcient to meet the person's needs and goals and
should be attempted initially before more costly and restrictive treat-
ments are attempted” [84,85]. Many of the HD patients are reluctant to
accept pharmacotherapy alone for symptoms, and it may even impair
their HRQOL due to additional pill burden or side-eﬀects from medi-
cation interactions [86,87]. In the Symptom Management Involving End-
Stage Renal Disease (SMILE) trial, < 30% of the depressed patients ac-
cepted anti-depressant medication recommendations [87,88]. In these
patients, uptake of CBT may be greater than that of medications – in a
3-month trial of chairside CBT for depression in HD patients, recruit-
ment rate was over 95%, and patients' volitional drop-out rate was less
than1% despite a high prevalence of personality disorders in the sample
[25]. This high adherence to behavioral therapy is in stark contrast to
the rates of medication non-adherence in these patients, which are es-
timated to be over 90% in some studies [14]. Thus, by oﬀering patients
a choice of treatment options, and involving them in shared decision-
making, TĀCcare provides an individualized real-world approach,
which is likely to have high patient acceptance and adherence. More-
over, by incorporating patient voice, it gives patients more control over
their treatment, and is likely to have higher patient engagement.
Secondly, by using technology to deliver CBT via video-conferen-
cing, TĀCcare overcomes patient related barriers of face-to-face CBT
such as additional doctors' appointments, transportation, costs, etc.
Furthermore, technology-delivered CBT allows for more eﬃcient use of
therapist time as compared to chair side CBT in dialysis units by saving
travel time for the therapist. Moreover, since self-guided computerized
CBT programs are unlikely to be successful in these patients due to the
high prevalence of poor health literacy, visual impairment, and limited
use/accessibility of technology-based health resources, especially in the
minority groups; TĀCcare provides a novel way to leverage technology
and deliver CBT in these patients [89]. There is growing evidence from
randomized controlled trials that behavioral interventions delivered via
interactive video-conferencing are as eﬃcacious as face-to-face inter-
ventions [90,91]. By utilizing minimal additional clinical resources, this
intervention can be scaled quickly, even to areas where trained thera-
pists may not be readily available. Additionally, by testing the inter-
vention in a diverse ethnic and racial cohort, our ﬁndings will be
readily generalizable across cultural/racial backgrounds and can be
readily adopted and widely disseminated in routine dialysis care.
This study will also reveal novel insights on the eﬀect of decreased
symptom burden on levels of inﬂammatory cytokines, which may have
huge implications for preventing cardiovascular morbidity and mor-
tality in HD patients [92,93]. There is also growing evidence on the
strong association of depressive symptoms, fatigue and chronic pain
with several inﬂammatory cytokines (IL-6, IL-10, TNF-α, and hs-CRP)
in HD patients and in the general population [9,16,18,69]. In cancer
patients, a theoretical framework of immune dysregulation causing
patient symptoms has been proposed through activation of the Hy-
pothalamic-Pituitary Adrenal (HPA) axis [94]. It is quite plausible that
a similar bidirectional relationship exists between immune system
dysfunction and symptom burden in HD patients as well. In HD pa-
tients, an association of inﬂammation and mortality is well-established
– a recent meta-analysis of over 100 studies concluded that high levels
of inﬂammatory cytokines (CRP and IL-6) are independent predictors of
increased all-cause and cardiovascular mortality [93,95]. Thus, sys-
temic inﬂammation may be a mechanistic link between these patient
symptoms and adverse outcomes including mortality in HD patients
(Fig. 1). Treatment of these symptoms in other chronic disease states
has been shown to decrease inﬂammatory burden, but evidence for
such improvements in bio-behavioral mediators in ESRD patients is
limited [25,69,96–99].
Despite these strengths, there are some limitations of the study to be
considered. Firstly, the intervention cannot be blinded. Thus, we have
employed several features to minimize bias including – a) randomized
controlled study design which generates the highest level of evidence
for comparative eﬀectiveness of treatments; and b) use of centralized
computer-assisted telephone interviewing for outcome measures which
maximizes patient participation, and ensures the assessors are blinded,
both of which minimize bias in an open-label clinical trial. Secondly,
there is a possibility that there may be increased symptom recognition
and management in the control arm by the renal providers. However,
this is unlikely given reluctance of patients and providers regarding
pharmacotherapy alone, and patient burden associated with in-oﬃce
CBT. However, we will monitor use of CBT and medications for
symptom management in the controls. Lastly, renal providers may be
reluctant to prescribe pharmacotherapy for symptom management.
However, the study will conduct renal provider education, oﬀer mul-
tidisciplinary approaches for symptom management, and provide a
framework for collaborative care to facilitate integration of symptom
management in the dialysis treatment plan [100].
10. Conclusion
TĀCcare is the ﬁrst, large multi-center randomized controlled trial
to test the eﬃcacy of a stepped-collaborative care intervention tar-
geting symptom clusters of depression, pain, and fatigue in HD patients.
It leverages novel technology-based tools and resources to potentially
alleviate these common symptoms and to improve HRQOL in a scalable,
resource-eﬃcient manner, while advancing mechanistic insights into
the underlying inﬂammatory process.
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